
Opinion|Videos|August 21, 2024
Clinical Scenario of a 32-Year-Old Female with AYA ALL and the Role of Cytogenetics in AYA ALL
Michael Grunwald, MD, presents the case of a 32-year-old woman with AYA ALL, and Kelly Weaver, NP, DNP, discusses the role of cytogenetics in diagnosing patients with AYA ALL.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- A 32-year-old female with a history of migraines and anxiety presented to the Emergency Department with a one-month history of fatigue and weakness and a two-day history of spontaneous bruising.
- The patient had been undergoing an outpatient workup for anemia with her primary care physician.
- In the ED, blood counts were noted to be abnormal. White blood cell count was 2.9k with neutrophils 8% and lymphocytes 89%, hemoglobin 4.2 g/dL, and platelet count 6k.
- Bone marrow examination revealed cellularity of 100% with 80% blasts expressing CD19, CD10, CD34, HLA-DR, CD38, CD43, CD22, and CD24. FISH and PCR for the BCR-ABL translocation were negative.
- No Ph-like abnormalities were detected.
- No malignant cells were identified in the cerebrospinal fluid.
- The patient was initiated on treatment per CALGB 10403.
Advertisement
Related to this article

Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.

Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.

Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5


